Aims Data on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with
atrial fibrillation (AF) and frailty are scarce. Therefore, the impact of frailty on AF-related …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Background Frailty is a medical syndrome characterised by reduced physiological reserve
and increased vulnerability to stressors. Data regarding the relationship between frailty and …

Elderly and frail patients with atrial fibrillation (AF) are at increased risk of thrombotic events,
bleeding, and death compared to their counterparts, making their management challenging …

Objectives To assess the risk of stroke/systemic embolism (SE) and major bleeding
associated with the use of oral anticoagulants in elderly patients with atrial fibrillation (AF) in …

Aims People with atrial fibrillation (AF) frequently live with frailty, which increases the risk of
mortality and stroke. This study reports the association between oral anticoagulation (OAC) …

Background The risks of thromboembolic and hemorrhagic events in patients with atrial
fibrillation both increase with age; therefore, net clinical benefit analyses of anticoagulant …

Background and Objective Atrial fibrillation (AF), the most common cardiac arrhythmia,
typically increases with age. Oral anticoagulants (OACs) are the cornerstone of treatment to …

Background Patient frailty amongst patients with nonvalvular atrial fibrillation (NVAF) is
associated with adverse health outcomes and increased risk of mortality. Additional …

BACKGROUND: Patients with atrial fibrillation (AF) and frailty are a considerable group in
clinical practice. However, existing studies provide insufficient evidence of anticoagulation …